Literature DB >> 3168146

PharmCalc: program for the calculation of clinical pharmacokinetic parameters of methotrexate.

J D Borsi1, O Klepp, P J Moe.   

Abstract

A new program package (PharmCalc) has been developed for the calculation of basic pharmacokinetic parameters (half-time, systemic clearance, renal clearance, AUC, volume of distribution, CSF/serum distribution ratio) of methotrexate (MTX). The program helps in the early recognition of patients at risk for toxicity and calculates the dosage of folinic acid rescue adjusted to the serum levels of MTX. The program offers a standardized and automated evaluation procedure for MTX pharmacokinetics and provides an easy-to-use tool for further research in this field. The concept and routines of the program are described.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3168146     DOI： 10.1007/bf00254242

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  7 in total

1.  Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

Authors:  W E Evans; C B Pratt; R H Taylor; L F Barker; W R Crom
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models.

Authors:  D L Weiner
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-10

3.  KINPAK--a program for standardized pharmacokinetic analysis.

Authors:  B Kaufmann
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-10

4.  AUC-RPP: BASIC computer program for compartment model independent pharmacokinetic analysis.

Authors:  W A Ritschel
Journal:  Methods Find Exp Clin Pharmacol       Date:  1986-10

5.  Prognostic importance of systemic clearance of methotrexate in childhood acute lymphoblastic leukemia.

Authors:  J D Borsi; T Revesz; D Schuler
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia.

Authors:  W E Evans; W R Crom; C F Stewart; W P Bowman; C H Chen; M Abromowitch; J V Simone
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

7.  [Radiational basis and practice of the citrovorum factor (Leucovorin) protection after high-dose methotrexate therapy. High-dose methotrexate/leucovorin].

Authors:  H Sauer; A Schalhorn
Journal:  Onkologie       Date:  1980-04
  7 in total
  1 in total

1.  Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.

Authors:  J D Borsi; D Schuler; P J Moe
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.